Literature DB >> 11454460

Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators.

C Chang1, S Kuo, Y Lin, J Wang, L Huang.   

Abstract

Several benzyloxybenzaldehyde analogues were prepared and found to have significant inhibitory activity toward neutrophil superoxide formation. Consequently, these compounds were evaluated for cAMP-elevating capability. Among them, benzyloxybenzaldehyde (7), exhibiting activity equivalent to forskolin, was determined as an adenylyl cyclase activator since it elevates cAMP levels by activation of adenylyl cyclase but not by inhibition of phosphodiesterase. Having a chemical structure very different from known adenylyl cyclase activators, compound 7 is recommended by us for use as a new lead compound in the future development of adenylyl cyclase activators.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454460     DOI: 10.1016/s0960-894x(01)00353-5

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  3 in total

1.  Synthesis of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazines that have antibacterial activity and also inhibit inorganic pyrophosphatase.

Authors:  Wei Lv; Biplab Banerjee; Katrina L Molland; Mohamed N Seleem; Adil Ghafoor; Maha I Hamed; Baojie Wan; Scott G Franzblau; Andrew D Mesecar; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2013-11-15       Impact factor: 3.641

2.  2-Benzyloxybenzaldehyde inhibits formyl peptide-stimulated increase in intracellular Ca2+ in neutrophils mainly by blocking Ca2+ entry.

Authors:  Jih-Pyang Wang; Ling-Chu Chang; Yu-Hsiang Kuan; Lo-Ti Tsao; Li-Jiau Huang; Sheng-Chu Kuo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-23       Impact factor: 3.000

3.  In vivo evaluation of the synthesized novel 2-benzyloxybenzaldehyde analog CCY-1a-E2 for the treatment of leukemia in the BALB/c mouse WEHI-3 allograft model.

Authors:  Chingju Lin; Jai-Sing Yang; Shih-Chang Tsai; Chin-Fen Lin; Miau-Rong Lee
Journal:  Oncol Lett       Date:  2012-12-17       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.